

Figure 1A







Figure 1B




Figure 1C




Figure 1D





Figure 2


Figure 2C


Figure 3A

Figure 3B




Figure 4A




Figure 4B




Figure 4C




Figure 5A




FIGURE 5 cont.







Figure 6

A



C



B




Figure 7A






Figure 7A cont.



Sample Name	positive :: Freq. of Parent
Unstained	1.06
Isotype C	1.12
EpCAM bispecific T cell activator	4.48
FAP bispecific T cell activator	84.7



Sample Name	positive :: Freq. of Parent
Unstained	0.78
Isotype C	0.22
EpCAM bispecific T cell activator	0.37
FAP bispecific T cell activator	78.4

Figure 7B




Figure 8A




Figure 8B




Figure 8C




Figure 9A




Figure 9B




Figure 10




Figure 11A




Figure 11B




Figure 12




Figure 13A




Figure 13B




Figure 14





Figure 15







Figure 17




Figure 18




Figure 19




Figure 20A




Figure 20B




Figure 21




Figure 22






Figure 23


EnAd-SA-Control bispecific T cell activator-
P2A-RFP



EnAd-SA-FAP bispecific T cell activator-
P2A-RFP



EnAd-CMV-Control bispecific T cell activator-
P2A-RFP



EnAd-CMV-FAP bispecific T cell activator-
P2A-RFP




Figure 24




Figure 25A




Figure 25B




Figure 26




Figure 27






Figure 28




- SKOV (unstained)
- NHDF (red)
- caspase stain (green)
- Virus – 100 vp/cell

Figure 29


**EnAd-CMV-Control bispecific T cell
activator/RFP**




**EnAd-CMV-FAP bispecific T cell
activator/RFP**



**EnAd-SA-Control bispecific T cell
activator/RFP**




**EnAd-SA-FAP bispecific T cell
activator/RFP**



- SKOV (unstained)
- NHDF (green)
- RFP virus (red) – MOI of 1 for CMV, 10 for SA

Figure 30

With T-cells added



No T-cells added





Figure 31

With T-cells added



No T-cells added




Figure 32





Figure 33

MOI: 10



Light grey – no T-cells added
Dark grey - T-cells added

MOI: 1





Figure 33 cont.

MOI: 0.1



Light grey –
no T-cells added
Dark grey -
T-cells added

MOI: 0.01





Figure 33 cont.

MOI: 0.001



Light grey –
no T-cells added
Dark grey -
T-cells added

MOI: 0






Figure 34

With T-cells added



No T-cells added




- Uninfected
- EnAd
- ▲ EnAd-CMV-Control bispecific T cell activator
- ▼ EnAd-CMV-EpCAM bispecific T cell activator
- ◊ EnAd-SA-Control bispecific T cell activator
- ◊ EnAd-SA-EpCAM bispecific T cell activator

- Uninfected
- EnAd
- ▲ EnAd-CMV-Control bispecific T cell activator
- ▼ EnAd-CMV-EpCAM bispecific T cell activator
- ◊ EnAd-SA-Control bispecific T cell activator
- ◊ EnAd-SA-EpCAM bispecific T cell activator

Figure 35

With T-cells added



No T-cells added




Figure 36




Figure 37






Figure 38

untreated

EnAd



- SKOV (unstained)
- NHDF (red)
- caspase stain (green)
- Virus – 100 vp/cell

EpCAM bispecific T cell activator

EnAd-CMV-EpCAM bispecific T cell activator






Figure 39

EnAd-CMV-GFP



EnAd-SA-GFP



Figure 40






Figure 41



EnAd-CMV-GFP

EnAd-SA-GFP

Media



Ascites
fluid







Figure 42





Figure 43







Figure 44

Figure 45A



B



C




Figure 45 cont.





Figure 45 cont.

Figure 45 cont.






Figure 45G



A



B




Figure 46




Figure 47





Figure 47 cont.

Figure 48





Figure 49A







Figure 49 cont.




Figure 49 cont.




Figure 50




Figure 50 cont.





Figure 50 cont.

G





Figure 50 cont.

A



B




Figure 51

C




Figure 51 cont.

D




Figure 51 cont.

E




Figure 51 cont.

A





Figure 52

B

Subset	Count
EpCAM	749
CD3	289
PD1	206
CD11b	277
Total	10000

Figure 52

A



B




Figure 53




Figure 53 cont.


E

0 hr


30 hr

48 hr


Untreated



EnAd



EnAd-CMV-
EpCAM bispecific
T cell activator



82/138

Figure 53 cont.




Figure 54




Figure 54 cont.




Figure 55





Figure 55 cont.

**Figure 56**




Figure 56 cont.

C




Figure 56 cont.

D




Figure 56 cont.




Figure 57

C







Figure 57 cont.


D EnAd



EnAd-CMV-EpCAM bispecific T cell activator



	Sample Name	Subset Name	Count
■	[conBiTE 1.063]	EpCAM-positive	310
■	[conBiTE 1.063]	CD25-positive	16.0
■	[conBiTE 1.063]	CD3	160
■	[conBiTE 1.063]	Cells only	9408



	Sample Name	Subset Name	Count
■	[epBiTE 1.066]	EpCAM-positive	6.00
■	[epBiTE 1.066]	CD25-positive	3214
■	[epBiTE 1.066]	CD3	3400
■	[epBiTE 1.066]	Ungated	10000

Figure 57 cont.




Figure 57 cont.

FIGURE 58




FIGURE 59




FIGURE 60




FIGURE 61




FIGURE 62



FIGURE 63




FIGURE 64




FIGURE 65




FIGURE 66A




FIGURE 66B




FIGURE 66C




FIGURE 67A




FIGURE 67B




FIGURE 67C





Figure 68

A



B




Figure 69




Figure 69






Figure 70

A



B





Figure 70

C



D




Figure 71




Figure 72





Figure 72**D**

Figure 73





Figure 73

Figure 74




Figure 75




Figure 75









Figure 76**EpCAM Staining****A****CD8 Staining****B****FAP Staining****C**

Figure 76**D**


Untreated



EnAd-CMV-control bispecific T cell activator



EnAd-CMV-FAP bispecific T cell activator



EnAd-SA-FAP bispecific T cell activator




Figure 76




Figure 77





Figure 77D


Figure 78


Figure 79


Figure 80




Figure 81A**Figure 81B**



Figure 83**Figure 84**


Figure 85


Figure 86




Figure 87**Figure 88****Figure 89**


Figure 90


Figure 91

Figure 92